CRBU (Caribou Biosciences) Float Percentage Of Total Shares Outstanding: 96.04% (As of Jul. 10, 2026)


CRBU Caribou Biosciences Inc CRBU
64 GF Score
Price $1.93
GF Value $1.68
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Caribou Biosciences Float Percentage Of Total Shares Outstanding?

Caribou Biosciences CRBU -0.77% 64 Float Percentage Of Total Shares Outstanding is 96.04% as of Jul. 10, 2026. GuruFocus rates CRBU with a GF Score™ of 64/100 and a GF Value™ of $1.68 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Caribou Biosciences's float shares is 95.25 Mil. Caribou Biosciences's total shares outstanding is 99.18 Mil. Caribou Biosciences's float percentage of total shares outstanding is 96.04%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Caribou Biosciences's Insider Ownership is 1.93%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Caribou Biosciences's Institutional Ownership is 42.50%.

CRBU
64GF Score
Caribou Biosciences Inc CRBU
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Caribou Biosciences Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Caribou Biosciences's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=95.25/99.18
=96.04%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 96.04% mean?
Caribou Biosciences (CRBU) has a Float Percentage Of Total Shares Outstanding of 96.04% as of Jul. 10, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Caribou Biosciences and its competitors.
Is Caribou Biosciences' Float Percentage Of Total Shares Outstanding too high?
Caribou Biosciences' current Float Percentage Of Total Shares Outstanding is 96.04%. Overall, Caribou Biosciences has a GF Score™ of 64/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Caribou Biosciences' Float Percentage Of Total Shares Outstanding compare to YDES and PRQR?
Caribou Biosciences' Float Percentage Of Total Shares Outstanding of 96.04% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Caribou Biosciences and its competitors. Caribou Biosciences's current Float Percentage Of Total Shares Outstanding is 96.04%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Caribou Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Caribou Biosciences (CRBU) is currently considered Modestly Overvalued. The stock's GF Value™ is $1.68, compared to a current price of $1.93 — trading 14.6% above its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 96.04%. Caribou Biosciences' overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Caribou Biosciences (CRBU), the current Float Percentage Of Total Shares Outstanding is 96.04% as of Jul. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Caribou Biosciences (CRBU) Overvalued in 2026?

Based on GuruFocus' analysis, Caribou Biosciences stock appears to be overvalued. The current stock price of $1.93 is trading 14.6% above its estimated GF Value™ of $1.68. GuruFocus considers Caribou Biosciences to be Modestly Overvalued.

Key valuation signals for CRBU:

  • Float Percentage Of Total Shares Outstanding: 96.04%
  • GF Value™: $1.68 vs. price of $1.93 (14.6% above fair value)
  • GF Score™: 64/100 with 5 warning signs

No single metric tells the full story. See the CRBU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Caribou Biosciences Business Description

Address 2929 7th Street, Suite 105, Berkeley, CA, USA, 94710
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.
64GF Score

Get the complete analysis for CRBU

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.93
Price
$1.68
GF Value